MEK inhibition and immune responses in advanced melanoma

phase II and III clinical trials demonstrated modest anti- tumor activity of Binimetinib (MEK162) - a potent allosteric inhibitor of MEK1 and MEK2- in patients with advanced NRAS mutant melanoma. The analysis of the NEMO study in NRAS mutated melanoma, has shown that pre-treatment with immunotherapy...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncoimmunology
Autori principali: Dummer, Reinhard, Ramelyte, Egle, Schindler, Sabrina, Thürigen, Olaf, Levesque, Mitchell P., Koelblinger, Peter
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2017
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5593717/
https://ncbi.nlm.nih.gov/pubmed/28919996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1335843
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi